Cargando…
Polypharmacy and relapse of schizophrenia: are they related?
INTRODUCTION: Polypharmacy can be the cause of deliberate discontinuation of medication and consequent relapse of schizophrenia. OBJECTIVES: To establish the one-year rate of relapse in the patients with schizophrenia with regard to monotherapy or polypharmacy. METHODS: The sample of all hospitalize...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567320/ http://dx.doi.org/10.1192/j.eurpsy.2022.1975 |
_version_ | 1784809371273789440 |
---|---|
author | Softic, R. Osmanovic, S. Becarevic, N. |
author_facet | Softic, R. Osmanovic, S. Becarevic, N. |
author_sort | Softic, R. |
collection | PubMed |
description | INTRODUCTION: Polypharmacy can be the cause of deliberate discontinuation of medication and consequent relapse of schizophrenia. OBJECTIVES: To establish the one-year rate of relapse in the patients with schizophrenia with regard to monotherapy or polypharmacy. METHODS: The sample of all hospitalized patients with schizophrenia in a five-year period was analyzed. Descriptive statistics were used. RESULTS: Total of 87 participants (57 women), the median age was 43 years. Antipsychotic monotherapy was used in 31 (35.6%) of the participants. In one year period, 32 (36.8%) of all participants had a relapse. Prior to relapse, significantly more participants were treated with polypharmacy (p<0,05). CONCLUSIONS: Antipsychotic polypharmacy is related to a higher rate of relapse in patients with schizophrenia. DISCLOSURE: No significant relationships. |
format | Online Article Text |
id | pubmed-9567320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95673202022-10-17 Polypharmacy and relapse of schizophrenia: are they related? Softic, R. Osmanovic, S. Becarevic, N. Eur Psychiatry Abstract INTRODUCTION: Polypharmacy can be the cause of deliberate discontinuation of medication and consequent relapse of schizophrenia. OBJECTIVES: To establish the one-year rate of relapse in the patients with schizophrenia with regard to monotherapy or polypharmacy. METHODS: The sample of all hospitalized patients with schizophrenia in a five-year period was analyzed. Descriptive statistics were used. RESULTS: Total of 87 participants (57 women), the median age was 43 years. Antipsychotic monotherapy was used in 31 (35.6%) of the participants. In one year period, 32 (36.8%) of all participants had a relapse. Prior to relapse, significantly more participants were treated with polypharmacy (p<0,05). CONCLUSIONS: Antipsychotic polypharmacy is related to a higher rate of relapse in patients with schizophrenia. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9567320/ http://dx.doi.org/10.1192/j.eurpsy.2022.1975 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Softic, R. Osmanovic, S. Becarevic, N. Polypharmacy and relapse of schizophrenia: are they related? |
title | Polypharmacy and relapse of schizophrenia: are they related? |
title_full | Polypharmacy and relapse of schizophrenia: are they related? |
title_fullStr | Polypharmacy and relapse of schizophrenia: are they related? |
title_full_unstemmed | Polypharmacy and relapse of schizophrenia: are they related? |
title_short | Polypharmacy and relapse of schizophrenia: are they related? |
title_sort | polypharmacy and relapse of schizophrenia: are they related? |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567320/ http://dx.doi.org/10.1192/j.eurpsy.2022.1975 |
work_keys_str_mv | AT softicr polypharmacyandrelapseofschizophreniaaretheyrelated AT osmanovics polypharmacyandrelapseofschizophreniaaretheyrelated AT becarevicn polypharmacyandrelapseofschizophreniaaretheyrelated |